ABBV vs. LLY: AbbVie vs. Eli Lilly Stock Comparison

July 7, 2026

How do AbbVie (ABBV) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while LLY is classified in Pharmaceuticals.

Company profile comparison for AbbVie (ABBV) and Eli Lilly (LLY)
Profile Item	ABBV	LLY
Name	AbbVie Inc.	Eli Lilly and Company
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Pharmaceuticals
GICS Sub-Industry	Biotechnology	Pharmaceuticals
Market Capitalization	450.11 billion USD	1,070.14 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	January 2, 2013	June 1, 1972
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ABBV

LLY

GSPC

AbbVie (ABBV) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for AbbVie (ABBV) and Eli Lilly (LLY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for AbbVie (ABBV) and Eli Lilly (LLY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and Eli Lilly (LLY)
Metric	ABBV	LLY
Total Return (1Y)	38.98%	54.81%
Total Return (3Y, Annualized)	27.38%	38.32%
Total Return (5Y, Annualized)	21.57%	39.82%

Risk Profile

Drawdown History

ABBV

LLY

GSPC

AbbVie (ABBV) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for AbbVie (ABBV) and Eli Lilly (LLY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AbbVie (ABBV) and Eli Lilly (LLY)
Metric	ABBV	LLY
Volatility (1Y, Annualized)	25.98%	38.66%
Beta (5Y)	0.30	0.51
Max Drawdown (5Y)	-21.92%	-34.48%
Avg. Volume (3M)	7.12M	3.25M

Risk-Adjusted Performance

Risk-Return Positioning

ABBV and LLY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and Eli Lilly (LLY)
Metric	ABBV	LLY
Sharpe Ratio (1Y)	1.35	1.32
Sortino Ratio (1Y)	2.13	2.01

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Eli Lilly (LLY) earns 107.46% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 100.65%
Q3: 2.17%
Median: -32.82%
Q1: -63.57%
Min: -158.89%
ABBV: --

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

107.46%

LLY: 107.46%
Max: 100.65%
Q3: 2.17%
Median: -32.82%
Q1: -63.57%
Min: -158.89%

AbbVie (ABBV) vs. Eli Lilly (LLY): ABBV does not report ROE, so it has no value marker; LLY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Both AbbVie (ABBV) at 5.79% and Eli Lilly (LLY) at 34.99% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.79%

ABBV: 5.79%
Max: 5.58%
Q3: 1.05%
Median: 0.00%
Q1: -2.00%
Min: -5.57%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.99%

LLY: 34.99%
Max: 5.58%
Q3: 1.05%
Median: 0.00%
Q1: -2.00%
Min: -5.57%

AbbVie (ABBV) vs. Eli Lilly (LLY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both AbbVie (ABBV) at 32.16% and Eli Lilly (LLY) at 49.39% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.16%

Max: 100.30%
ABBV: 32.16%
Q3: 3.00%
Median: 0.00%
Q1: -133.46%
Min: -337.81%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

49.39%

Max: 100.30%
LLY: 49.39%
Q3: 3.00%
Median: 0.00%
Q1: -133.46%
Min: -337.81%

AbbVie (ABBV) vs. Eli Lilly (LLY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and Eli Lilly (LLY)
Metric	ABBV	LLY
ROE (TTM)	--	107.46%
ROA (TTM)	10.03%	20.74%
Net Margin (TTM)	5.79%	34.99%
Operating Margin (TTM)	32.16%	49.39%
Gross Margin (TTM)	72.03%	82.83%

Growth

Revenue Growth

AbbVie (ABBV) vs. Eli Lilly (LLY): A comparison of their Revenue Growth across different time periods.

Revenue Growth Metrics

Revenue growth metrics for AbbVie (ABBV) and Eli Lilly (LLY)
Metric	ABBV	LLY
Revenue Growth (YoY)	8.57%	44.70%
Revenue Growth (3Y CAGR)	1.75%	31.69%

EPS Growth

AbbVie (ABBV) vs. Eli Lilly (LLY): A comparison of their EPS Growth across different time periods.

EPS Growth Metrics

EPS growth metrics for AbbVie (ABBV) and Eli Lilly (LLY)
Metric	ABBV	LLY
EPS Growth (YoY)	-1.26%	95.99%
EPS Growth (3Y CAGR)	-29.13%	51.71%

Financial Strength

Current Ratio (MRQ)

Both AbbVie (ABBV) at 0.80 and Eli Lilly (LLY) at 1.50 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.80

Max: 26.16
Q3: 12.13
Median: 5.81
Q1: 2.70
ABBV: 0.80
Min: 0.23

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.50

Max: 26.16
Q3: 12.13
Median: 5.81
Q1: 2.70
LLY: 1.50
Min: 0.23

AbbVie (ABBV) vs. Eli Lilly (LLY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Eli Lilly (LLY) carries debt-to-equity ratio of 1.39 against its industry range, while AbbVie (ABBV) reports no figure this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.60
Q3: 0.68
Median: 0.15
Q1: 0.02
Min: 0.00
ABBV: --

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max: 1.60
LLY: 1.39
Q3: 0.68
Median: 0.15
Q1: 0.02
Min: 0.00

AbbVie (ABBV) vs. Eli Lilly (LLY): ABBV does not report debt-to-equity ratio, so it has no value marker; LLY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and Eli Lilly (LLY)
Metric	ABBV	LLY
Current Ratio (MRQ)	0.80	1.50
Debt / Equity (MRQ)	--	1.39
Net Debt / EBITDA	2.12	1.05

Dividends

Dividend Yield (TTM)

Both AbbVie (ABBV) at 2.58% and Eli Lilly (LLY) at 0.51% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.58%

ABBV: 2.58%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.51%

LLY: 0.51%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Eli Lilly (LLY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 325.98%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Eli Lilly (LLY) reports 22.13%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

325.98%

ABBV: 325.98%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

22.13%

LLY: 22.13%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

AbbVie (ABBV) vs. Eli Lilly (LLY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and Eli Lilly (LLY)
Metric	ABBV	LLY
Dividend Yield (TTM)	2.58%	0.51%
Dividend Payout Ratio (TTM)	325.98%	22.13%

Valuation

P/E Ratio (TTM)

Eli Lilly (LLY) at 42.62 is near its industry’s usual P/E ratio, while AbbVie (ABBV) at 124.88 sits above its peer range — an unusually expensive price for ABBV’s trailing earnings.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

124.88

ABBV: 124.88
Max: 84.76
Q3: 48.50
Median: 26.28
Q1: 15.88
Min: 2.09

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.62

Max: 84.76
Q3: 48.50
LLY: 42.62
Median: 26.28
Q1: 15.88
Min: 2.09

AbbVie (ABBV) vs. Eli Lilly (LLY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both AbbVie (ABBV) at 7.17 and Eli Lilly (LLY) at 14.81 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.17

Max: 68.43
Q3: 29.55
Median: 8.01
ABBV: 7.17
Q1: 3.56
Min: 0.01

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.81

Max: 68.43
Q3: 29.55
LLY: 14.81
Median: 8.01
Q1: 3.56
Min: 0.01

AbbVie (ABBV) vs. Eli Lilly (LLY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -67.63, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Eli Lilly (LLY) reports 34.37, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-67.63

Max: 15.41
Q3: 7.29
Median: 3.81
Q1: 1.69
Min: -6.68
ABBV: -67.63

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.37

LLY: 34.37
Max: 15.41
Q3: 7.29
Median: 3.81
Q1: 1.69
Min: -6.68

AbbVie (ABBV) vs. Eli Lilly (LLY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and Eli Lilly (LLY)
Metric	ABBV	LLY
P/E Ratio (TTM)	124.88	42.62
P/S Ratio (TTM)	7.17	14.81
P/B Ratio (MRQ)	-67.63	34.37
Free Cash Flow Yield (TTM)	4.62%	0.86%